Peroxisome proliferatoractivated receptors - PowerPoint PPT Presentation

1 / 32
About This Presentation
Title:

Peroxisome proliferatoractivated receptors

Description:

Center for Molecular Toxicology and Carcinogenesis, ... is evidence that activation of PPARb/d can either potentiate or attenuate cancer. ... – PowerPoint PPT presentation

Number of Views:118
Avg rating:3.0/5.0
Slides: 33
Provided by: nci397
Category:

less

Transcript and Presenter's Notes

Title: Peroxisome proliferatoractivated receptors


1
Peroxisome proliferator-activated receptors in
health and disease
Jeffrey M. Peters Associate Professor Center for
Molecular Toxicology and Carcinogenesis, The
Pennsylvania State University, University Park, PA

2
Hepatic Peroxisome Proliferation
3
PPARs
  • Nuclear hormone receptor superfamily
  • Multiple isoforms (?, ? (d), ?)
  • Unique tissue distribution

4
Sequence Comparison of PPARS
5
PPAR Activators/Ligands
PPAR? Fatty acids (derivatives), hypolipidemic
drugs (fibrates, Wy-14,643), industrial
solvents/plasticizers (pthalates) PPAR?
Prostaglandin J2, thiozoladinediones
(troglitazone, etc) PPAR?/d Fatty acids,
fatty acid derivatives (L-165,041, GW1516, GW0742)
6
Activation of PPARs by Phthalate Monoesters
There is a large species difference in the
concentration of phthalate monoesters required to
activate PPARs. Bility, M. et al, Tox. Sci., 2004
7
Mechanism of PPAR action
?
Co-repressors Co-activators
PPARRXR?
?
?
Modulation of gene transcription
Biological effect
8
Mechanism of PPAR action
9
Biological roles of PPARa
PPARa mediates the induction of multiple enzymes
required to mobilize and transport fatty acids
from adipose stores to liver for catabolism.
Basis for therapeutic use in humans to lower
serum lipids.
10
Biological roles of PPARa
PPARa mediates the hepatocarcinogenic effect
induced by peroxisome proliferators in rodents,
human relevance is questionable.
11
Biological roles of PPARb/d
Ligand activation of PPARb/d leads to terminal
differentiation of keratinocytes as shown by four
independent laboratories. Activation of PPARb/d
in skeletal muscle leads to increased catabolism
of fatty acids and improved insulin sensitivity.
12
Biological roles of PPARb/d
The role of PPARb/d in carcinogenesis is
controversial. There is evidence that activation
of PPARb/d can either potentiate or attenuate
cancer.
13
Biological roles of PPARg
Activation of PPARg leads to improved insulin
sensitivity and lower serum glucose during
hyperglycemia. Basis for therapeutic use as
anti-diabetic drugs.
14
Biological roles of PPARg
The role of PPARg in carcinogenesis is also
controversial. There is evidence that activation
of PPARg can either potentiate or attenuate
cancer, but current consensus favors
attenuation.
15
Orchestration of Immune Responses
CELLS Lymphocytes Monocytes/Macs Neutrophils Eosin
ophils Basophils Dendritic cells
MOLECULES Complement Lysozyme Inflammatory
mediators Chemokines Cytokines
TISSUES Thymus Spleen Lymph nodes Blood
Innate immunity Adaptive Immunity
PPARs are found in a number of immune cell types
and there is evidence that they could modulate a
number of different immune responses
16
Role of PPARa in Immune Function
  • Expressed in monocytes/macrophages, increased
    after treatment with phorbol ester
  • PPARa ligands induce apoptosis in activated
    macrophages
  • PPARa ligands decrease secretion of MMPs in
    LPS-treated monocytes
  • PPARa ligands decrease NOS activity in
    macrophages
  • BUT
  • Natural PPARa ligands increase NOS activity in
    macrophages

17
Role of PPARa in Immune Function
  • Inflammatory response induced by LTB4 is enhanced
    in PPARa-null mice
  • PPARa ligands can inhibit inflammatory cytokine
    production
  • BUT
  • PPARa ligands cause increase in serum TNFa after
    LPS

18
Role of PPARa in Immune Function
  • More reports suggest that PPARa ligands are
    anti-inflammatory but there are also some reports
    suggesting that PPARa ligands are pro-inflammatory

19
Role of PPARa in Immune Function
  • PPARa mediates ligand induced decrease in T-cells
    and B-cells.
  • Alternative mechanism of anti-inflammatory action?

Yang, Q. et al Biochem. Pharm. 2002
20
Role of PPARb/d in Immune Function
  • PPARb/d is expressed in many immune cell types,
    is induced in macrophages by phorbol ester

21
Role of PPARb/d in Immune Function
  • Enhanced neutrophil accumulation in TPA-treated
    PPARb/d-null (/) mouse skin suggests that
    PPARb/d is anti-inflammatory

22
Role of PPARb/d in Immune Function
  • PPARb/d ligand inhibits myeloperoxidase activity,
    independent of the receptor

23
Role of PPARb/d in Immune Function
  • Inhibition of MPO activity by all three PPAR
    ligands

24
Role of PPARb/d in Immune Function
  • PPARb/d ligand inhibits LPS-stimulated iNOS, COX2
    and TNFa in macrophages
  • Welch, J et al, PNAS, 2003

25
Role of PPARb/d in Immune Function
  • PPARb/d ligands are anti-inflammatory, some of
    these effects are independent of the receptor.

26
Role of PPARg in Immune Function
  • PPARg is expressed in macrophages and splenic
    dendritic cells
  • PPARg ligands inhibit inflammatory cytokines in
    macrophages and monocytes
  • BUT..
  • PPARg ligands up-regulate pro-inflammatory
    surface receptors (CD14, CD11b/CD18, SRB1)

27
Role of PPARg in Immune Function
  • Inhibition of iNOS and IL-6 in macrophages by
    PPARg ligand (rosiglitazone) is dependent on
    PPARg at 10 µM but not at 50 µM.
    Welch, J et al, PNAS, 2003

28
Role of PPARg in Immune Function
  • PPARg ligands inhibit antigen-stimulated
    responses of T-cell clones
  • PPARg ligands mediate inhibition of anti-CD3
    antibody-stimulated proliferative responses of
    T-cell clones and freshly isolated enriched
    splenocytes
  • The mechanisms underlying these responses are
    unclear but could involve inhibition of IL-2
    secretion and/or apoptosis
  • Clark, R, et al J. Immun. 2000
  • Yang, X, et al JBC, 2000
  • Harris, SG, et al, Eur. J. Immun., 2001

29
Role of PPARg in Immune Function
  • PPARg ligands also inhibit B-cell growth
  • Padilla, J, et al J. Immun. 2000

30
Summary
  • Activation of PPARa is used therapeutically
    because it can reduce serum lipids.
  • Activation of PPARg is used therapeutically
    because it increases insulin sensitivity
  • Activation of PPARb/d is being explored as a
    mechanism to increase insulin sensitivity
  • Activation of PPARa causes hepatocarcinogenesis
  • Controversial literature regarding the role of
    PPARb/d and PPARg in cancer

31
Summary
  • While there are highly specific ligands for all
    three PPARs, there is accumulating evidence that
    there are off-site targets for these ligands
    (e.g. inhibition of MPO, etc). Null mouse studies
    will be useful for determining off-site
    targets.
  • There is good evidence that ligands for all three
    PPARs are anti-inflammatory, and some of these
    effects may be mediated by the receptor (e.g.
    interaction with NF-kB, etc) or independent of
    the receptor (e.g. off-site targets, etc).
  • PPARa/g ligands can influence T-cells and
    B-cells, role of these changes on immune function
    uncertain.

32
Human Relevance
  • Hepatocarcinogenic effect of PPARa ligands
    appears to be rodent-specific.
  • Null mouse studies clearly demonstrate receptor
    requirement, but there can be differences in
    receptor function between species.
  • PPARg ligands (rosiglitazone and pioglitazone)
    are currently being used as anti-diabetic agents,
    on-going analysis may provide clues for role of
    ligands/receptor on cancer, immune function.
  • Clinical trials have also been performed to
    examine efficacy of PPARg ligands to inhibit
    carcinogenesis.
  • PPARb/d ligands are being developed, effect in
    humans currently unclear.
Write a Comment
User Comments (0)
About PowerShow.com